| HOME >> MEDICINE >> TECHNOLOGY |
9.1 Technology and Market Trends 93
9.2 M&A Activity 94
9.3 Partnering 94
9.4 Competitive Situation 96
9.5 Intellectual Property Rights 97
9.6 Industry Challenges and Strategic Recommendations for Commercialization 98
9.7 Opportunities and Strategic Recommendations 99
9.8 Requirements for a Successful Cancer Vaccine Products Industry 102
10. Company Profiles 106
10.1 Advaxis 106
10.2 Agenus (formerly Antigenics) 106
10.3 AlphaVax 106
10.4 Antigen Express 107
10.5 Apthera 107
10.6 Argos Therapeutics 107
10.7 AVAX Technologies 107
10.8 Bavarian Nordic 108
10.9 Bellicum Pharmaceuticals 108
10.10 BioSante Pharmaceuticals 108
10.11 Biovest International 108
10.12 Celldex Therapeutics 109
10.13 CG Therapeutics 109
10.14 CureVac 109
10.15 DanDrit Biotech 109
10.16 Dendreon 110
10.17 EMD Serono 110
10.18 Geron 110
10.19 GlaxoSmithKline 110
10.20 GlobeImmune 111
10.21 Immatics Biotechnologies 111
10.22 ImmunoCellular Therapeutics 111
10.23 Immunovaccine 111
10.24 Inovio Pharmaceuticals 111
10.25 KAEL-Gemvax 112
10.26 MannKind 112
10.27 Mologen AG 112
10.28 NewLink Genetics Corporation 112
10.29 Northwest Biotherapeutics 113
10.30 NovaRx 113
10.31 Oxford BioMedica 113
10.32 Prima BioMed 113
10.33 Scancell 113
10.34 Transgene 113
10.35 Trimed Biotech 114
10.36 Vaccinogen 114
10.37 Vical 114
INDEX OF FIGURES
Figure 2.1: Estimates of National Expenditures for Cancer Care in 2006 by Cancer
Site 14
Figure 2.2: Person-Years of Life Lost (PYLL) in the U.S. Due to Cancer, Male,
2006 15
Figure 2.3: Person-Years of Life Lost (PYLL) in the U.S. Due to Cancer, Female,
2006 16
Fig
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |